DBV Technologies S.A. — Q2 2021 Form 10-Q
Reporting period: Three and six months ended June 30, 2021. Financial amounts below are in U.S. dollars; unless noted, figures are in millions. DBV is a clinical-stage biopharmaceutical company developing epicutaneous immunotherapy using its Viaskin platform. It had no product sales or product revenue.
Financial performance and position
| Metric | Q2 2021 | Q2 2020 | Six months 2021 | Six months 2020 |
|---|---|---|---|---|
| Operating income (loss) | $(1.5) | $3.6 | $1.5 | $8.3 |
| Operating expenses | $29.6 | $51.3 | $62.2 | $97.2 |
| Loss from operations | $(31.1) | $(47.7) | $(60.8) | $(88.9) |
| Net loss | $(30.7) | $(48.2) | $(60.1) | $(89.1) |
| Basic/diluted loss per share | $(0.56) | $(0.88) | $(1.09) | $(1.67) |
| Cash used in operating activities | Not provided for quarter | Not provided for quarter | $(66.5) | $(89.8) |
Operating income reflects French research tax credits and collaboration-related income, not product sales. No sales-based margins are meaningful. Six-month research and development expense was $42.3 million, sales and marketing $1.9 million, and general and administrative $18.0 million.
At June 30, 2021, cash and cash equivalents were $125.5 million, down from $196.4 million at year-end 2020. Current assets were $138.6 million and current liabilities $38.7 million. Total liabilities were $57.6 million, including $0.9 million of financial debt and $11.9 million of operating lease liabilities; the filing does not identify significant conventional borrowings. The six-month cash decrease was $70.9 million, including $5.4 million of adverse foreign-exchange effects. Investing cash use was minimal ($0.013 million); financing provided $1.1 million.
Changes versus prior comparable periods
- Six-month net loss narrowed by about 33%, while operating cash use decreased by about 26%, principally reflecting lower spending and the prior-year restructuring charge.
- Total operating expenses fell 36% in the first half. R&D expenses fell 14%, sales and marketing 70%, and G&A 10%. There were no restructuring expenses in the first half of 2021, versus $21.3 million in the first half of 2020.
- Operating income fell from $8.3 million to $1.5 million for the first half. Management attributed this primarily to lower collaboration income, following updated estimates of progress and costs for the Nestlé Health Science Phase II trial, and lower research tax credits.
- Cash declined from $196.4 million at December 31, 2020 to $125.5 million at June 30, 2021; the comparable 2020 period included $150.7 million in financing proceeds from an equity offering.
Outlook, developments, and risks
- U.S. regulatory path: The FDA’s 2020 Complete Response Letter cited patch adhesion and modification, the need for supporting clinical data, and additional manufacturing information—not safety concerns. FDA feedback in January 2021 outlined a path forward, including assessment of allergen uptake comparability and a six-month safety and adhesion study. DBV reported that five modified patches had better adhesion in a healthy-adult study and selected two for further development. It submitted the STAMP study protocol to FDA and was awaiting feedback; it also initiated PREQUAL to support planned uptake-comparability work.
- Europe: EMA review of the Viaskin Peanut application continued. In July 2021, DBV received the Day 180 list of outstanding issues; one Major Objection remained. Management estimated a possible EMA decision in Q4 2021 or Q1 2022. This was an estimate, not assured guidance.
- Pipeline: Enrollment in Part B of the EPITOPE study in children ages 1–3 was completed in Q1 2021. The filing gives no clear timing for results.
- Liquidity outlook: Management stated that June 30 cash was expected to fund operations for at least the next 12 months, and elsewhere described runway through the second half of 2022. It intended to seek additional capital as it prepared for a potential product launch and continued R&D. Future financing availability and terms were uncertain.
- COVID-19 and trial costs: The pandemic disrupted trial enrollment and required protocol adaptations. DBV expected additional clinical and production costs for the Nestlé-collaboration trial; its related loss-at-completion contingency rose to $9.1 million from $4.0 million at year-end 2020. The company also cited possible financing-market disruption.
- Restructuring: Average headcount was 111 in the first half, compared with 311 in the prior-year period; 97 employees remained at June 30. Management expected organization-wide cost reductions to be fully implemented in the second half of 2021. Restructuring liabilities were $2.9 million at June 30.
- Legal matter: On July 29, 2021, the court dismissed a securities class-action complaint without prejudice and allowed plaintiffs until September 30 to amend it. DBV said it believed the claims were without merit and did not expect a material adverse financial effect.
Management reported effective disclosure controls as of June 30, 2021 and no material change in internal control over financial reporting. The filing reported no material change in risk factors from the 2020 Form 10-K.
Important facts for investors to verify
- Progress, timing, cost, and FDA feedback for STAMP and the planned allergen-uptake comparability assessment, including any future BLA resubmission schedule.
- Resolution of the remaining EMA Major Objection and whether the estimated Q4 2021–Q1 2022 decision window remains viable.
- Cash burn and runway against the stated funding horizon, including the need, timing, and terms of additional financing.
- Enrollment and cost assumptions for the Nestlé-collaboration trial, and whether the $9.1 million loss-at-completion contingency changes.
- Any amended securities class-action complaint and subsequent court developments.